| Sep 4 |
Serina Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
| Jul 29 |
Serina Therapeutics to Present Novel Data on POZ-Lipid Technology Potentially Enhancing Safety and Efficacy of mRNA LNP Formulations at the 4th mRNA-Based Therapeutics Summit
|
| Jul 18 |
Serina Therapeutics Appoints Srini Tenjarla, Ph.D. as Senior Vice President of CMC and Formulation
|
| May 15 |
Parkinson's-focused Serina Therapeutics, Enable Injections enter partnership
|
| May 15 |
Enable Injections and Serina Therapeutics Announce Agreement to Develop SER-252 in Combination with enFuse® for Advanced Parkinson’s Disease
|
| May 14 |
AgeX Therapeutics GAAP EPS of -$3.38, revenue of $0.05M
|
| May 14 |
Serina Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights
|
| May 3 |
Serina Therapeutics files to sell 1.5M shares of common stock
|
